Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
66,788,293
-
Shares change
-
+843,688
-
Total reported value, excl. options
-
$1,473,155,747
-
Value change
-
+$29,409,971
-
Put/Call ratio
-
18%
-
Number of buys
-
87
-
Number of sells
-
-49
-
Price
-
$22.10
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2019
164 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q2 2019.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66,788,293 shares
of 116,964,738 outstanding shares and own 57% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6,822,188 shares), Temasek Holdings (Private) Ltd (6,556,116 shares), BlackRock Inc. (5,037,431 shares), JPMORGAN CHASE & CO (4,263,805 shares), FMR LLC (3,372,527 shares), Kohlberg Kravis Roberts & Co. L.P. (3,055,055 shares), VANGUARD GROUP INC (2,958,583 shares), STATE STREET CORP (2,440,954 shares), LORD, ABBETT & CO. LLC (2,414,338 shares), and Sofinnova Investments, Inc. (2,093,221 shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.